Display options
Cite
Neckermann P, Boilesen DR, Willert T, et al. Design and Immunological Validation of . Front Immunol. 2021;12:761214doi: 10.3389/fimmu.2021.761214.
Neckermann, P., Boilesen, D. R., Willert, T., Pertl, C., Schrödel, S., Thirion, C., Asbach, B., Holst, P. J., & Wagner, R. (2021). Design and Immunological Validation of . Frontiers in immunology, 12761214. https://doi.org/10.3389/fimmu.2021.761214
Neckermann, Patrick, et al. "Design and Immunological Validation of ." Frontiers in immunology vol. 12 (2021): 761214. doi: https://doi.org/10.3389/fimmu.2021.761214
Neckermann P, Boilesen DR, Willert T, Pertl C, Schrödel S, Thirion C, Asbach B, Holst PJ, Wagner R. Design and Immunological Validation of . Front Immunol. 2021 Oct 28;12:761214. doi: 10.3389/fimmu.2021.761214. eCollection 2021. PMID: 34777375; PMCID: PMC8581358.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2021 Oct 28;12:761214. doi: 10.3389/fimmu.2021.761214. eCollection 2021.

Design and Immunological Validation of .

Frontiers in immunology

Patrick Neckermann, Ditte Rahbaek Boilesen, Torsten Willert, Cordula Pertl, Silke Schrödel, Christian Thirion, Benedikt Asbach, Peter Johannes Holst, Ralf Wagner

Affiliations

  1. Institute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany.
  2. Centre for Medical Parasitology, the Panum Institute, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
  3. InProTher APS, Copenhagen, Denmark.
  4. SIRION Biotech GmbH, Munich, Germany.
  5. Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.

PMID: 34777375 PMCID: PMC8581358 DOI: 10.3389/fimmu.2021.761214

Abstract

Persistent human papillomavirus (HPV) infections are causative for cervical neoplasia and carcinomas. Despite the availability of prophylactic vaccines, morbidity and mortality induced by HPV are still too high. Thus, an efficient therapy, such as a therapeutic vaccine, is urgently required. Herein, we describe the development and validation of

Copyright © 2021 Neckermann, Boilesen, Willert, Pertl, Schrödel, Thirion, Asbach, Holst and Wagner.

Keywords: DNA vaccine; HPV; MfPV3; adenoviral vector; immunogen design; invariant chain; therapeutic vaccine

Conflict of interest statement

PH is an inventor on a patent detailing the use of the invariant chain as an adjuvant for virally delivered vaccines owned by the University of Copenhagen. The right to use the patent for treating HPV

References

  1. Infect Agent Cancer. 2018 Nov 16;13:35 - PubMed
  2. PLoS One. 2011;6(4):e18556 - PubMed
  3. J Infect Dis. 2015 Feb 15;211(4):549-57 - PubMed
  4. Sci Rep. 2017 May 19;7(1):2193 - PubMed
  5. Syst Synth Biol. 2010 Sep;4(3):215-25 - PubMed
  6. J Virol. 2002 Nov;76(22):11350-8 - PubMed
  7. J Virol. 1999 Sep;73(9):7297-307 - PubMed
  8. Methods Mol Biol. 2014;1089:143-58 - PubMed
  9. JAMA. 2007 Aug 15;298(7):743-53 - PubMed
  10. Mol Ther. 2014 May;22(5):1039-47 - PubMed
  11. J Immunother. 2017 Feb/Mar;40(2):51-61 - PubMed
  12. J Virol. 1989 Jun;63(6):2650-6 - PubMed
  13. Oncoimmunology. 2018 Jul 26;7(10):e1487913 - PubMed
  14. Vaccine. 2018 Oct 1;36(41):6212-6222 - PubMed
  15. Am J Clin Pathol. 1994 Dec;102(6):768-74 - PubMed
  16. Virology. 2009 Oct 25;393(2):304-10 - PubMed
  17. Lancet Oncol. 2012 Jan;13(1):89-99 - PubMed
  18. Cancer Res. 2010 Jul 1;70(13):5316-25 - PubMed
  19. Front Microbiol. 2019 Sep 10;10:2093 - PubMed
  20. Clin Cancer Res. 2020 Apr 1;26(7):1616-1623 - PubMed
  21. CA Cancer J Clin. 2021 May;71(3):209-249 - PubMed
  22. N Engl J Med. 1998 Feb 12;338(7):423-8 - PubMed
  23. Open Virol J. 2012;6:241-8 - PubMed
  24. J Gen Virol. 2007 Mar;88(Pt 3):803-813 - PubMed
  25. Scand J Immunol. 2017 Mar;85(3):182-190 - PubMed
  26. J Immunol. 2019 Apr 15;202(8):2320-2331 - PubMed
  27. Expert Opin Biol Ther. 2008 Apr;8(4):421-39 - PubMed
  28. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301 - PubMed
  29. PLoS Genet. 2010 Sep 02;6(9):e1001085 - PubMed
  30. J Virol. 2002 Aug;76(15):7616-24 - PubMed
  31. Cancer Res. 2004 Aug 1;64(15):5449-55 - PubMed
  32. Eur J Immunol. 2007 Feb;37(2):376-84 - PubMed
  33. J Immunol. 2008 Mar 1;180(5):3339-46 - PubMed
  34. Cancers (Basel). 2019 Jan 15;11(1): - PubMed
  35. J Transl Med. 2015 Nov 25;13:370 - PubMed
  36. Theranostics. 2017 Aug 23;7(16):3814-3823 - PubMed
  37. Lancet HIV. 2019 Nov;6(11):e737-e749 - PubMed
  38. J Virol. 2005 Jul;79(14):8828-34 - PubMed
  39. J Virol. 2007 Jun;81(12):6339-45 - PubMed
  40. Int J Cancer. 2010 Jan 1;126(1):133-41 - PubMed
  41. Front Immunol. 2017 Feb 22;8:149 - PubMed
  42. Infect Agent Cancer. 2013 Jun 06;8(1):20 - PubMed
  43. J Immunol. 2014 Aug 1;193(3):1223-32 - PubMed
  44. Sci Transl Med. 2020 Jun 17;12(548): - PubMed
  45. J Med Virol. 2013 Apr;85(4):646-54 - PubMed
  46. J Virol. 2019 Jan 17;93(3): - PubMed
  47. Cancer Gene Ther. 2012 Oct;19(10):667-74 - PubMed
  48. J Virol. 2004 Mar;78(5):2615-9 - PubMed
  49. PLoS One. 2014 Sep 29;9(9):e108892 - PubMed
  50. Methods Mol Biol. 2019;1988:109-122 - PubMed
  51. J Immunol. 2011 Apr 1;186(7):3997-4007 - PubMed
  52. Sci Rep. 2019 Dec 10;9(1):18713 - PubMed
  53. Sci Rep. 2018 Jan 24;8(1):1474 - PubMed
  54. Immunohorizons. 2020 Jan 2;4(1):1-13 - PubMed
  55. Vaccine. 2012 Nov 20;30 Suppl 5:F123-38 - PubMed
  56. Gynecol Oncol. 2006 Jul;102(1):22-31 - PubMed
  57. J Gen Virol. 2009 Feb;90(Pt 2):414-422 - PubMed

Publication Types